Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lixia Yi
Observed names:
L. Yi,
Li-Xia Yi,
Yi, Lixia
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0000-0001-7642-3139
Observed ORCID:
0000-0001-7642-3139
OpenAlex ID:
A5103156099
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
2024
·
L. Yi
, Z. Ning
, et al.
·
ESMO Open
·
44
PDF
Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1+ cancer-associated fibroblast in gastric cancer
2024
·
Xiya Jia
, Ziteng Li
, et al.
·
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
·
22
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial
2024
·
Lixia Yi
, Haoqi Pan
, et al.
·
Signal Transduction and Targeted Therapy
·
21
PDF
Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report
2023
·
Lixia Yi
, Xiaoyan Zhu
, et al.
·
Human Vaccines & Immunotherapeutics
·
3
PDF
95P A phase II study of combination of H101 (a recombinant human adenovirus type 5) and nivolumab for advanced hepatocellular carcinoma (HCC) after systemic therapy failure
2022
·
J. Xie
, L. Yi
, et al.
·
Immuno-Oncology Technology
·
1
Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ERK/DRP1 Pathway
2026
·
Wai-Mei Si
, Xin Li
, et al.
·
The American Journal of Chinese Medicine
Abstract 662: Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: A phase II trial
2025
·
Lixia Yi
, Zhiqiang Meng
, et al.
·
Cancer Research
Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report
2023
·
Yi, Lixia
, Zhu, Xiaoyan
, et al.
·
Figshare
Show more works
View as search
Works count:
8
Citation count:
91
H-index:
3
I10-index:
3
Year
Topic
Type